MYO Overview

Key Data

  • Open $10.32
  • Day Range 10.16 - 10.86
  • 52 Week Range 3.42 - 18.88
  • Market Cap $57.83M
  • Shares Outstanding 5.6M
  • Public Float 5.04M
  • Beta N/A
  • Rev. per Employee $118.49K
  • P/E Ratio N/A
  • EPS -$2.76
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 186.6K 05/28/21
  • % of Float Shorted 3.70%
  • Average Volume 85.07K

Performance

5 Day
  • -0.39%
1 Month
  • 14.24%
3 Month
  • -18.41%
YTD
  • 51.41%
1 Year
  • 194.51%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

Myomo started at buy with $36.50 stock price target at Alliance Global

Jun. 10, 2021 at 7:53 a.m. ET by Tomi Kilgore
Barron's

Susquehanna: 3 Microcap Stocks It’s Buying and 1 Mid-Cap

Dec. 22, 2017 at 1:04 p.m. ET by Barron's

Myomo's stock more than doubles on heavy volume after reporting big jump in revenue

Nov. 7, 2017 at 12:04 p.m. ET by Tomi Kilgore
  • Other News
  • Press Releases

Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

May. 5, 2021 at 7:05 p.m. ET on Zacks.com

Colliers Securities Sticks to Their Buy Rating for Myomo (MYO)

May. 5, 2021 at 12:45 p.m. ET on SmarterAnalyst

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Apr. 28, 2021 at 12:34 p.m. ET on Zacks.com

Myomo (MYO) Gets a Buy Rating from Colliers Securities

Mar. 11, 2021 at 7:41 a.m. ET on SmarterAnalyst

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

Mar. 10, 2021 at 5:55 p.m. ET on Zacks.com

Analysts Offer Insights on Healthcare Companies: Myomo (MYO) and Opthea Limited Sponsored ADR (OPT)

Mar. 8, 2021 at 7:45 a.m. ET on SmarterAnalyst

Myomo (MYO) Gets a Buy Rating from Colliers Securities

Mar. 8, 2021 at 4:06 a.m. ET on SmarterAnalyst

Colliers Securities Keeps Their Buy Rating on Myomo (MYO)

Mar. 8, 2021 at 4:05 a.m. ET on SmarterAnalyst

Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Mar. 4, 2021 at 12:31 p.m. ET on Zacks.com

Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic

Feb. 17, 2021 at 10:55 a.m. ET on Zacks.com

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical

Feb. 17, 2021 at 6:01 a.m. ET on Zacks.com

BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test

Feb. 16, 2021 at 10:33 a.m. ET on Zacks.com

Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe

Feb. 9, 2021 at 9:56 a.m. ET on Zacks.com

Boston Scientific (BSX) Hurt by Product Recall, Conversion

Feb. 9, 2021 at 9:41 a.m. ET on Zacks.com

Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging

Jan. 28, 2021 at 8:02 a.m. ET on Zacks.com

Allscripts (MDRX) Extends Tie-Up With US Orthopedic Alliance

Jan. 27, 2021 at 8:55 a.m. ET on Zacks.com

Hill-Rom (HRC) to Boost Cardiology Portfolio with New Buyout

Jan. 21, 2021 at 9:46 a.m. ET on Zacks.com

Myomo Sees Sales More Than Double In 4Q; Shares Jump 6%

Jan. 11, 2021 at 9:41 a.m. ET on TipRanks.com

3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021

Dec. 11, 2020 at 8:35 a.m. ET on Zacks.com

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Aug. 10, 2020 at 6:35 p.m. ET on Zacks.com

Myomo Inc.

Myomo, Inc. is a medical robotics company, which offers expanded mobility for those suffering from neurological disorders and upper-limb paralysis. It offers MyoPro, which is a myoelectric elbow, wrist, and hand orthosis that supports an impaired hand and arm while also enabling it to move again. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

Competitors

Name Chg % Market Cap
Patterson Cos. Inc. 0.63% $3.4B
Oncologix Tech Inc. -2.70%
Novation Holdings Inc. 0.00%
Competitor Data Provided ByCapital Cube Logo